Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12622001464752
Ethics application status
Approved
Date submitted
1/11/2022
Date registered
18/11/2022
Date last updated
18/11/2022
Date data sharing statement initially provided
18/11/2022
Type of registration
Prospectively registered
Titles & IDs
Public title
Exposure Therapy for Functional Neurological Disorders
Query!
Scientific title
Exposure Therapy for Functional Neurological Disorders - an open-label, prospective, randomised, wait-list controlled, feasibility pilot study
Query!
Secondary ID [1]
308282
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ET-FND
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Functional Neurological Disorders
328067
0
Query!
Condition category
Condition code
Neurological
325127
325127
0
0
Query!
Other neurological disorders
Query!
Mental Health
325270
325270
0
0
Query!
Other mental health disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This pilot trial will assess the efficacy of Skills Training in Affective and Interpersonal Regulation (STAIR) in Functional Neurological Disorders (FND). STAIR is an established psychological treatment for Posttraumatic Stress Disorder (PTSD). STAIR Therapy consists of two separate phases: the skills-focused STAIR phase (8 sessions) and the trauma exposure phase (8 sessions). The STAIR phase of treatment is dedicated to interventions designed to target emotional regulation and social impairments. Specifically, skills aimed to enhance emotion regulation capacities and improve interpersonal effectiveness are taught and fostered over the course of eight sessions. The second phase of treatment introduces the creation of a series of narratives where clients are asked to provide a description of traumatic experiences out loud in a detailed, organized and emotionally engaged fashion. This phase of treatment is implemented in the individual format. Skills practice continues throughout the second phase and successes in day-to-day events are discussed to highlight differences between traumatic events being described and life in the “here and now.” Emotion regulation skills are employed during the narrative work as needed. Successful progression through treatment allows for the meaningful reorganization of traumatic memories and reinforces the emotion regulation skills work completed in the initial STAIR phase. The treatment goals and associated interventions in the STAIR phase include (1) promoting emotional awareness through the identification and labeling of feelings and their triggers as they emerge in daily life; (2) teaching emotion regulation strategies to modulate negative feelings and tolerate distress via adaptive affective expression through actions, words and thoughts; (3) fostering the adaptive use of emotions and distress tolerance to facilitate achievement of social goals; (4) encouraging the identification and modification of maladaptive interpersonal schemas that are influencing interpersonal functioning; (5) facilitating the identification of adaptive and achievable social goals in the context of different types of relationships and interpersonal situations; and (6) attaining a sense of emotional and social self-efficacy that facilitates living in the world with compassion and empathy. Participants will be encouraged to complete 'homework' tasks each week. This includes breathing retraining taught in the first session of STAIR (target practice 5 minutes, twice daily); completion of a 'feelings monitoring form' (completed minimum twice daily for minimum 1-week, 2-3 minutes per completion), interpersonal schema worksheet (completed over two weeks, 20-30 mins in total); listening to a recording of an exposure narrative completed with the therapist in a treatment session (listen to recording once daily for 1-week).
In this study, treatment will involve 16, one hour sessions completed over 16-weeks. All sessions will take place face-to-face at the Neuropsychology East Melbourne clinic located in Victoria, or via Telehealth so people from regional areas and interstate can participate. All 16 sessions (including those in the STAIR phase) will be conducted one-to-one by a psychologist trained in this model of therapy following a therapist manual (resource adapted from Cloitre M et al., 2002, Skills training in affective and interpersonal regulation followed by exposure). Clinical supervision will be overseen by Prof Sarah Wilson and Prof Kim Felmingham who collectively are highly experienced working with this patient group and in STAIR Therapy.
Therapist adherence to the intervention will gauged via 1) completion of a session checklist (completed by the trial therapist) to ensure treatment targets are met; and 2) independent assessment of audio recordings of each treatment session completed with participants.
Query!
Intervention code [1]
324735
0
Treatment: Other
Query!
Intervention code [2]
324871
0
Behaviour
Query!
Comparator / control treatment
Wait-list control group. The control group involves FND patients who will be randomly allocated to a 16-week wait list and continue their standard care as usual. After this time, they will then be offered the same intervention as the treatment group.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
332944
0
Clinician-Rated Global Assessment of Functioning (GAF-C)
Query!
Assessment method [1]
332944
0
Query!
Timepoint [1]
332944
0
Completed by the treating clinician (psychologist) at Baseline and 16-weeks later (coinciding with the end of the intervention/wait-list control)
Query!
Secondary outcome [1]
415256
0
Participant rated quality of life assessed via the EQ-5D
Query!
Assessment method [1]
415256
0
Query!
Timepoint [1]
415256
0
Baseline (just prior to randomisation into the treatment/waitlist control group) and 4, 8, 12 and 16 weeks after baseline
Query!
Secondary outcome [2]
415257
0
Depression and anxiety symptoms assessed via participant self report on the Hospital Anxiety and Depression Scale (HADS)
Query!
Assessment method [2]
415257
0
Query!
Timepoint [2]
415257
0
Baseline (just prior to randomisation into the treatment/waitlist control group) and 4, 8, 12 and 16 weeks after baseline
Query!
Secondary outcome [3]
415259
0
Quality of life assessed via participant self-report on the Short-form 36 Health Survey (SF36)
Query!
Assessment method [3]
415259
0
Query!
Timepoint [3]
415259
0
Baseline (just prior to randomisation into the treatment/waitlist control group) and 4, 8, 12 and 16 weeks after baseline
Query!
Secondary outcome [4]
415260
0
Participant self-rated Global Assessment of Functioning (GAF)
Query!
Assessment method [4]
415260
0
Query!
Timepoint [4]
415260
0
Baseline (just prior to randomisation into the treatment/waitlist control group) and 4, 8, 12 and 16 weeks after baseline
Query!
Secondary outcome [5]
415261
0
Self reported seizure frequency (for individuals who experience seizures as part of their FND)
Query!
Assessment method [5]
415261
0
Query!
Timepoint [5]
415261
0
Baseline (just prior to randomisation into the treatment/waitlist control group) and 4, 8, 12 and 16 weeks after baseline
Query!
Secondary outcome [6]
415322
0
Feasibility of the trial measured by a composite of:
a) Proportion of patients who are screened and deemed eligible to participate
b) Willingness of patients to be consented and randomised
c) Number of therapy sessions attended by participants
Query!
Assessment method [6]
415322
0
Query!
Timepoint [6]
415322
0
a) A research assistant, in conjunction with the chief investigator, will collate these figures whilst the trial is recruiting
b) A research assistant, in conjunction with the chief investigator, will collate the number of participants who consent and are randomised into the trial
c) the trial psychologist will record attendance rates to the sessions throughout the
intervention period
Query!
Eligibility
Key inclusion criteria
• A diagnosis of FND by DSM-V (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) criteria
• Identified trauma preceding symptom onset within the last 5 years – this will be determined by the use of the Life Events and Difficulties Schedule (LEDS) administered by study staff prior to participant randomisation into the trial
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• Not fluent in English
• Unable to give informed consent
• Under 18 years of age
• Cognitive impairment
• Drug or Alcohol use disorder
• Currently undertaking psychological therapy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomised 1-1 at the point of recruitment by the chief investigator to intervention or waiting list followed by the intervention. A randomisation table created by computer software (i.e. computerised sequence generation) will be used to develop the sequence generation (simple randomisation method).
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
The statistical analysis plan will be agreed before unblinding of the database based on the study protocol. All analyses for all the outcomes will include all randomised patients. The feasibility parameters will be estimated by relevant summary statistics. For example, the proportion of eligible patients who agree to be randomised will be estimated by the relative frequency of patients agreeing to randomisation once confirmed eligible. Feasibility parameter estimates will be accompanied by 95% CIs. Treatment differences between the intervention and control will be explored. For continuous outcomes, mean differences between the intervention and treatment as usual will be estimated (including 95% CI) at week 16 and at follow-up using a linear regression model that accounts for baseline. Outcomes with a right skewed distribution will be log transformed first before fitting this model. For binary outcomes, we will use log-binomial regression to estimate risk ratios (including 95% CIs) at week 16 and follow-up. Missing scale item data will be handled as per questionnaire specific recommendations. Missing data reasons and the proportion of missing data in the outcomes will be compared between arms. The number and proportion of patients with (serious) adverse events will be reported.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
9/01/2023
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
12
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
23466
0
Austin Health - Heidelberg Repatriation Hospital - Heidelberg West
Query!
Recruitment postcode(s) [1]
38870
0
3081 - Heidelberg West
Query!
Funding & Sponsors
Funding source category [1]
312531
0
Hospital
Query!
Name [1]
312531
0
Austin Health (Austin Medical Research Fund)
Query!
Address [1]
312531
0
145 Studley Road
Heidelberg VIC 3084
Query!
Country [1]
312531
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Austin Health
Query!
Address
145 Studley Road
Heidelberg VIC 3084
Query!
Country
Australia
Query!
Secondary sponsor category [1]
314130
0
None
Query!
Name [1]
314130
0
Query!
Address [1]
314130
0
Query!
Country [1]
314130
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
311864
0
Austin Health Human Research Ethics Committee
Query!
Ethics committee address [1]
311864
0
Austin Health IBC Research Ethics Office for Research Level 8, Harold Stokes Building 145 Studley Road Austin Health Heidelberg VIC 3084
Query!
Ethics committee country [1]
311864
0
Australia
Query!
Date submitted for ethics approval [1]
311864
0
Query!
Approval date [1]
311864
0
28/07/2021
Query!
Ethics approval number [1]
311864
0
HREC/69935/Austin-2020
Query!
Summary
Brief summary
Functional Neurological Disorders (FND) are neurological problems that are thought to have a psychiatric cause. Though they are very common - the commonest reason for a referral to a neurologist – and very disabling, we know very little about how to treat them. This study would try out a new treatment – or rather, try out a very old treatment that has never been tested for FND before. Sigmund Freud proposed, 120 years ago, that FND (then known as hysteria) were a post-traumatic disorder - an abnormal reaction to stressful life events - and that the way to treat them was by getting patients to fully experience their traumatic memories, rather than avoiding them. This proved to be the best way to treat post-traumatic stress disorder (PTSD), in what is known as ‘prolonged exposure therapy’. However, it has never really been tested for FND, probably because deciding what the traumas are is difficult. In PTSD it is easy, because the traumas are life-threatening events, such as those that occur in warfare; in FND it is hard, because the traumas are less dramatic, such as a fight with a spouse or being bullied by your boss. We have developed a method for identifying these traumas in FND, and have confirmed that FND is a post-traumatic disorder – symptoms began following a traumatic life event in over 90% of cases. The next step is to see if the treatment that works so well for PTSD will work in FND. We propose to adapt the standard therapy by incorporating our method of identifying the traumas in FND, and then performing exposure therapy on those traumas. We will recruit patients from FND services at Austin Health, and then randomly allocate them to 16 sessions of exposure therapy, or a waiting list control. We will then compare the symptoms and quality of life in our patients at the beginning and end of the therapy to see if it has made a difference, when compared to the controls. We will then offer the same therapy to those on the waiting list. If successful, it will form the pilot for a larger grant for a full-scale trial of the therapy, and would represent an historic breakthrough in the management of this ancient condition.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
122642
0
Prof Richard Kanaan
Query!
Address
122642
0
Level 10, Lance Townsend Building
Austin Hospital
145 Studley Rd
Heidelberg VIC 3084
Query!
Country
122642
0
Australia
Query!
Phone
122642
0
+61394963351
Query!
Fax
122642
0
Query!
Email
122642
0
[email protected]
Query!
Contact person for public queries
Name
122643
0
Richard Kanaan
Query!
Address
122643
0
Level 10, Lance Townsend Building
Austin Hospital
145 Studley Rd
Heidelberg VIC 3084
Query!
Country
122643
0
Australia
Query!
Phone
122643
0
+61394963351
Query!
Fax
122643
0
Query!
Email
122643
0
[email protected]
Query!
Contact person for scientific queries
Name
122644
0
Richard Kanaan
Query!
Address
122644
0
Level 10, Lance Townsend Building
Austin Hospital
145 Studley Rd
Heidelberg VIC 3084
Query!
Country
122644
0
Australia
Query!
Phone
122644
0
+61394963351
Query!
Fax
122644
0
Query!
Email
122644
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Participants have not provided consent for data sharing
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF